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Abstract
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views
of the genome and transcriptome from representative numbers of patients. We present an
integrated analysis of copy number and gene expression in a discovery and validation set of 997
and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants
(copy number variants and single nucleotide polymorphisms) and acquired somatic copy number
aberrations (CNAs) were associated with expression in ~40% of genes, with the landscape
dominated by cis- and trans-acting CNAs. By delineating expression outlier genes driven in cis by
CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and
MAP2K4. Unsupervised analysis of paired DNA–RNA profiles revealed novel subgroups with
distinct clinical outcomes, which reproduced in the validation cohort. These include a high-risk,
oestrogen-receptor-positive 11q13/14 cis-acting subgroup and a favourable prognosis subgroup
devoid of CNAs. Trans-acting aberration hotspots were found to modulate subgroup-specific gene
networks, including a TCR deletion-mediated adaptive immune response in the ‘CNA-devoid’
subgroup and a basal-specific chromosome 5 deletion-associated mitotic network. Our results
provide a novel molecular stratification of the breast cancer population, derived from the impact of
somatic CNAs on the transcriptome.
Inherited genetic variation and acquired genomic aberrations contribute to breast cancer
initiation and progression. Although somatically acquired CNAs are the dominant feature of
sporadic breast cancers, the driver events that are selected for during tumorigenesis are
difficult to elucidate as they co-occur alongside a much larger landscape of random non-
pathogenic passenger alterations1,2 and germline copy number variants (CNVs). Attempts to
define subtypes of breast cancer and to discern possible somatic drivers are still in their
relative infancy3–6, in part because breast cancer represents multiple diseases, implying that
large numbers (many hundreds or thousands) of patients must be studied. Here we describe
an integrated genomic/transcriptomic analysis of breast cancers with long-term clinical
outcomes composed of a discovery set of 997 primary tumours and a validation set of 995
tumours from METABRIC (Molecular Taxonomy of Breast Cancer International
Consortium).
A breast cancer population genomic resource
We assembled a collection of over 2,000 clinically annotated primary fresh-frozen breast
cancer specimens from tumour banks in the UK and Canada (Supplementary Tables 1–3).
Nearly all oestrogen receptor (ER)-positive and/or lymph node (LN)-negative patients did
not receive chemotherapy, whereas ER-negative and LN-positive patients did. Additionally,
none of the HER2+ patients received trastuzumab. As such, the treatments were
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homogeneous with respect to clinically relevant groupings. An initial set of 997 tumours
was analysed as a discovery group and a further set of 995 tumours, for which complete data
later became available, was used to test the reproducibility of the integrative clusters
(described below). An overview of the main analytical approaches is provided in
Supplementary Fig. 1. Details concerning expression and copy number profiling, including
sample assignment to the PAM50 intrinsic subtypes3,4,7 (Supplementary Fig. 2), copy
number analysis (Supplementary Tables 4–8) and validation (Supplementary Figs 3 and 4
and Supplementary Tables 9–11), and TP53 mutational profiling (Supplementary Fig. 5) are
described in the Supplementary Information.
Genome variation affects tumour expression architecture
Genomic variants are considered to act in cis when a variant at a locus has an impact on its
own expression, or in trans when it is associated with genes at other sites in the genome. We
generated a map of CNAs, CNVs (Supplementary Fig. 6, Supplementary Tables 12–15) and
single nucleotide polymorphisms (SNPs) in the breast cancer genome to distinguish
germline from somatic variants (see Methods), and to examine the impact of each of these
variants on the expression landscape. Previous studies8 have shown that most heritable gene
expression traits are governed by a combination of cis (proximal) loci, defined here as those
within a 3-megabase (Mb) window surrounding the gene of interest, and trans (distal) loci,
defined here as those outside that window. We assessed the relative influence of SNPs,
CNVs and CNAs on tumour expression architecture, using each of these variants as a
predictor (see Methods) to elucidate expression quantitative trait loci (eQTLs) among
patients.
Both germline variants and somatic aberrations were found to influence tumour expression
architecture, having an impact on >39% (11,198/28,609) of expression probes genome-wide
based on analysis of variance (ANOVA; see Methods), with roughly equal numbers of genes
associated in cis and trans. CNAs were associated with the greatest number of expression
profiles (Fig. 1, Supplementary Figs 7–13 and Supplementary Tables 16–20), but were
rivalled by SNPs to explain a greater proportion of expression variation on a per-gene basis
genome-wide, whereas the contribution from CNVs was more moderate (Fig. 1b and
Supplementary Table 21). The true ratio of putative trans versus cis eQTLs is hard to
estimate9; however, the large sample size used here allowed the detection of small effects,
with 5,401 and 5,462 CNAs significantly (Šidák adjusted P value <0.0001) associated in cis
or in trans, respectively. Whereas cis-associations tended to be stronger, the trans-acting loci
modulated a larger number of messenger RNAs, as described below.
Expression outliers refine the breast cancer landscape
As shown above, ~20% of loci exhibit CNA-expression associations in cis (Supplementary
Fig. 14). To refine this landscape further and identify the putative driver genes, we used
profiles of outlying expression (see Methods and ref. 10) and the high resolution and
sensitivity of the Affymetrix SNP 6.0 platform to delineate candidate regions. This approach
markedly reduces the complexity of the landscape to 45 regions (frequency > 5, Fig. 2) and
narrows the focus, highlighting novel regions that modulate expression. The full
enumeration of regions delineated by this approach and their subtype-specific associations
(Supplementary Figs 15 and 16 and Supplementary Tables 22–24) includes both known
drivers (for example, ZNF703 (ref. 11), PTEN (ref. 12), MYC, CCND1, MDM2, ERBB2,
CCNE1 (ref. 13)) and putative driver aberrations (for example, MDM1, MDM4, CDK3,
CDK4, CAMK1D, PI4KB, NCOR1).
The deletion landscape of breast cancer has been poorly explored, with the exception of
PTEN. We illustrate three additional regions of significance centred on PPP2R2A (8p21,
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Fig. 2, region 11), MTAP (9p21, Fig. 2, region 15) and MAP2K4 (17p11, Fig. 2, region 33),
which exhibit heterozygous and homozygous deletions (Supplementary Figs 15, 17–19 and
Supplementary Table 24) that drive expression of these loci. We observe breast cancer
subtype-specific (enriched in mitotic ER-positive cancers) loss of transcript expression in
PPP2R2A, a B-regulatory subunit of the PP2A mitotic exit holoenzyme complex. Somatic
mutations in PPP2R1A have recently been reported in clear cell ovarian cancers and
endometrioid cancers14,15, and methylation silencing of PPP2R2B has also been observed in
colorectal cancers16. Thus, dysregulation of specific PPP2R2A functions in luminal B breast
cancers adds a significant pathophysiology to this subtype.
MTAP (9p21, a component of methyladenosine salvage) is frequently co-deleted with the
CDKN2A and CDKN2B tumour suppressor genes in a variety of cancers17 as we observe
here (Supplementary Figs 17c and 18). The third deletion encompasses MAP2K4 (also
called MKK4) (17p11), a p38/Jun dual specificity serine/threonine protein kinase. MAP2K4
has been proposed as a recessive cancer gene18, with mutations noted in cell lines19. We
show, for the first time, the recurrent deletion of MAP2K4 (Supplementary Figs 17d and 19)
concomitant with outlying expression (Supplementary Fig. 15) in predominantly ER-
positive cases, and verify homozygous deletions (Supplementary Table 9) in primary
tumours, strengthening the evidence for MAP2K4 as a tumour suppressor in breast cancer.
Trans-acting associations reveal distinct modules
We next asked how trans-associated expression profiles are distributed across the genome.
We mapped these in the expression landscape by examining the matrices of CNA–
expression associations (see Methods). This revealed strong off-diagonal patterns at loci on
chromosomes 1q, 7p, 8, 11q, 14q, 16, 17q and 20q (Fig. 3a), including both positive and
negative associations, as well as numerous trans-acting aberration hotspots (defined as
CNAs associated with >30 mRNAs). Importantly, these aberration hotspots can be grouped
into pathway modules, which highlight known driver loci such as ERBB2 and MYC, as well
as novel loci associated with large trans expression modules (Supplementary Tables 25 and
26). The T-cell-receptor (TCR) loci on chromosomes 7 (TRG) and 14 (TRA) represent two
such hotspots that modulated 381 and 153 unique mRNAs, respectively, as well as 19 dually
regulated genes (Supplementary Fig. 20). These cognate mRNAs were highly enriched for
T-cell activation and proliferation, dendritic cell presentation, and leukocyte activation,
which indicate the induction of an adaptive immune response associated with tumour-
infiltrating lymphocytes (Fig. 3b, Supplementary Fig. 20 and Supplementary Tables 27 and
28), as described later.
In a second approach, we examined the genome-wide patterns of linear correlation between
copy number and expression features (see Methods), and noted the alignment of several off-
diagonal signals, including those on chromosome 1q, 8q, 11q, 14q and 16 (Supplementary
Fig. 21). Additionally, a broad signal on chromosome 5 localizing to a deletion event
restricted to the basal-like tumours was observed (Supplementary Fig. 21), but was not
detected with the eQTL framework, where discrete (as opposed to continuous) copy number
values were used. This basal-specific trans module is enriched for transcriptional changes
involving cell cycle, DNA damage repair and apoptosis (Supplementary Table 29),
reflecting the high mitotic index typically associated with basal-like tumours, described in
detail below.
Integrative clustering reveals novel subgroups
Using the discovery set of 997 breast cancers, we next asked whether novel biological
subgroups could be found by joint clustering of copy number and gene expression data. On
the basis of our finding that cis-acting CNAs dominated the expression landscape, the top
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1,000 cis-associated genes across all subtypes (Supplementary Table 30) were used as
features for input to a joint latent variable framework for integrative clustering20 (see
Methods). Cluster analysis suggested 10 groups (based on Dunn’s index) (see Methods and
Supplementary Figs 22 and 23), but for completeness, this result was compared with the
results for alternative numbers of clusters and clustering schemes (see Methods,
Supplementary Figs 23–27 and Supplementary Tables 31–33). The 10 integrative clusters
(labelled IntClust 1–10) were typified by well-defined copy number aberrations (Fig. 4,
Supplementary Figs 22, 28–30 and Supplementary Tables 34–39), and split many of the
intrinsic subtypes (Supplementary Figs 31–33). Kaplan–Meier plots of disease-specific
survival and Cox proportional hazards models indicate subgroups with distinct clinical
outcomes (Fig. 5, Supplementary Figs 34, 35 and Supplementary Tables 40 and 41). To
validate these results, we trained a classifier (754 features) for the integrative subtypes in the
discovery set using the nearest shrunken centroids approach21 (see Methods and
Supplementary Tables 42 and 43), and then classified the independent validation set of 995
cases into the 10 groups (Supplementary Table 44). The reproducibility of the clusters in the
validation set is shown in three ways. First, classification of the validation set resulted in the
assignment of a similar proportion of cases to the 10 subgroups, each of which exhibited
nearly identical copy number profiles (Fig. 4). Second, the groups have substantially similar
hazard ratios (Fig. 5b, Supplementary Fig. 35 and Supplementary Table 40). Third, the
quality of the clusters in the validation set is emphasized by the in-group proportions (IGP)
measure22 (Fig. 4).
Among the integrative clusters, we first note an ER-positive subgroup composed of
11q13/14 cis-acting luminal tumours (IntClust 2, n = 45) that harbour other common
alterations. This subgroup exhibited a steep mortality trajectory with elevated hazard ratios
(discovery set: 3.620, 95% confidence interval (1.905–6.878); validation set: 3.353, 95%
confidence interval (1.381–8.141)), indicating that it represents a particularly high-risk
subgroup. Several known and putative driver genes reside in this region, namely CCND1
(11q13.3), EMSY (11q13.5), PAK1 (11q14.1) and RSF1 (11q14.1), which have been
previously linked to breast13,23 or ovarian cancer24. Both the copy number (Fig. 4) and
expression outlier landscapes (Fig. 2) suggest at least two separate amplicons at 11q13/14,
one at CCND1 (11q13.3) and a separate peak from 11q13.5-11q14.1 spanning UVRAG–
GAB2, centred around PAK1, RSF1, C11orf67 and INTS4, where it is more challenging to
distinguish the driver24. Notably, the expression outlier profiles for this region are enriched
for samples belonging to IntClust 2 (Fig. 2, inset region 23) and all 45 members of this
subgroup harboured amplifications of these genes, with high frequencies of amplification
also observed for CCND1 (n = 39) and EMSY (n = 34). In light of these observations, the
11q13/14 amplicon may be driven by a cassette of genes rather than a single oncogene.
Second, we note the existence of two subgroups marked by a paucity of copy number and
cis-acting alterations. These subgroups cannot be explained by low cellularity tumours (see
Methods). One subgroup (IntClust3, n = 156) with low genomic instability (Fig. 4 and
Supplementary Fig. 22) was composed predominantly of luminal A cases, and was enriched
for histotypes that typically have good prognosis, including invasive lobular and tubular
carcinomas. The other subgroup (IntClust 4, n = 167) was also composed of favourable
outcome cases, but included both ER-positive and ER-negative cases and varied intrinsic
subtypes, and had an essentially flat copy number landscape, hence termed the ‘CNA-
devoid’ subgroup. A significant proportion of cases within this subgroup exhibit extensive
lymphocytic infiltration (Supplementary Table 45).
Third, several intermediate prognosis groups of predominantly ER-positive cancers were
identified, including a 17q23/20q cis-acting luminal B subgroup (IntClust 1, n = 76), an
8p12 cis-acting luminal subgroup (IntClust 6, n = 44), as well as an 8q cis-acting/20q-
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amplified mixed subgroup (IntClust 9, n = 67). Two luminal A subgroups with similar CNA
profiles and favourable outcome were noted. One subgroup is characterized by the classical
1q gain/16q loss (IntClust 8, n = 143), which corresponds to a common translocation
event25, and the other lacks the 1q alteration, while maintaining the 16p gain/16q loss with
higher frequencies of 8q amplification (IntClust 7, n = 109). We also noted that the majority
of basal-like tumours formed a stable, mostly high-genomic instability subgroup (IntClust
10, n = 96). This subgroup had relatively good long-term outcomes (after 5 years),
consistent with ref. 26, and characteristic cis-acting alterations (5 loss/8q gain/10p gain/12p
gain).
The ERBB2-amplified cancers composed of HER2-enriched (ER-negative) cases and
luminal (ER-positive) cases appear as IntClust 5 (n = 94), thus refining the ERBB2 intrinsic
subtype by grouping additional patients that might benefit from targeted therapy. Patients in
this study were enrolled before the general availability of trastuzumab, and as expected this
subgroup exhibits the worst disease-specific survival at both 5 and 15 years and elevated
hazard ratios (discovery set: 3.899, 95% confidence interval (2.234–6.804); validation set:
4.447, 95% confidence interval (2.284–8.661)).
Pathway deregulation in the integrative subgroups
Finally, we projected the molecular profiles of the integrative subgroups onto pathways to
examine possible biological themes among breast cancer subgroups (Supplementary Tables
46 and 47) and the relative impact of cis and trans expression modules on the pathways. The
CNA-devoid (IntClust 4) group exhibits a strong immune and inflammation signature
involving the antigen presentation pathway, OX40 signalling, and cytotoxic T-lymphocyte-
mediated apoptosis (Supplementary Fig. 36). Given that trans-acting deletion hotspots were
localized to the TRG and TRA loci and were associated with an adaptive immune response
module, we asked whether these deletions contribute to alterations in this pathway. The
CNA-devoid subgroup (IntClust 4) was found to exhibit nearly twice as many deletions
(typically heterozygous loss) at the TRG and TRA loci (~20% of cases) as compared to the
other subtypes (with the exception of IntClust 10), and deletions of both TCR loci were
significantly associated with severe lymphocytic infiltration (χ2 test, P < 10−9 and P < 10−8,
respectively). Notably, these trans-associated mRNAs were significantly enriched in the
immune response signature of the CNA-devoid subgroup (Supplementary Fig. 36) as well as
among genes differentially expressed in CNA-devoid cases with severe lymphocytic
infiltration (Supplementary Fig. 37). We conclude that genomic copy number loss at the
TCR loci drives a trans-acting immune response module that associates with lymphocytic
infiltration, and characterizes an otherwise genomically quiescent subgroup of ER-positive
and ER-negative patients with good prognosis. These observations suggest the presence of
mature T lymphocytes (with rearranged TCR loci), which may explain an immunological
response to the cancer. In line with these findings, a recent study27 demonstrated the
association between CD8+ lymphocytes and favourable prognosis.
Also among the trans-influenced groups is IntClust 10 (basal-like cancer enriched
subgroup), which harbours chromosome 5q deletions (Supplementary Fig. 21). Numerous
signalling molecules, transcription factors and cell division genes were associated in trans
with this deletion event in the basal cancers, including alterations in AURKB, BCL2, BUB1,
CDCA3, CDCA4, CDC20, CDC45, CHEK1, FOXM1, HDAC2, IGF1R, KIF2C, KIFC1,
MTHFD1L, RAD51AP1, TTK and UBE2C (Supplementary Fig. 38). Notably, TTK
(MPS1), a dual specificity kinase that assists AURKB in chromosome alignment during
mitosis, and recently reported to promote aneuploidy in breast cancer28, was upregulated.
These results indicate that 5q deletions modulate the coordinate transcriptional control of
genomic and chromosomal instability and cell cycle regulation within this subgroup.
Curtis et al. Page 6









In contrast to these subtype-specific trans-associated signatures, the high-risk 11q13/14
subgroup was characterized by strong cis-acting associations. Like the basal cancers, this
subgroup also exhibited alterations in key cell-cycle-related genes (Supplementary Fig. 39),
which probably have a role in its aggressive pathophysiology, but the nature of the signature
differs. In particular, the regulation of the G1/S transition by BTG family proteins, which
include CCND1, PPP2R1B and E2F2, was significantly enriched in the 11q13/14 cis-acting
subgroup, but not the basal cancers, and this is consistent with CCND1 and the PPP2R
subunit representing subtype-specific drivers in these tumours.
Discussion
We have generated a robust, population-based molecular subgrouping of breast cancer based
on multiple genomic views. The size and nature of this cohort made it amenable to eQTL
analyses, which can aid the identification of loci that contribute to the disease phenotype29.
CNAs and SNPs influenced expression variation, with CNAs dominating the landscape in
cis and trans. The joint clustering of CNAs and gene expression profiles further resolves the
considerable heterogeneity of the expression-only subgroups, and highlights a high-risk
11q13/14 cis-acting subgroup as well as several other strong cis-actingclusters and a
genomically quiescent group. The reproducibility of subgroups with these molecular and
clinical features in a validation cohort of 995 tumours suggests that by integrating multiple
genomic features it may be possible to derive more robust patient classifiers. We show here,
for the first time, that subtype-specific trans-acting aberrations modulate concerted
transcriptional changes, such as the TCR deletion-mediated adaptive immune response that
characterizes the CNA-devoid subgroup and the chromosome 5 deletion-associated cell
cycle program in the basal cancers.
The integrated CNA-expression landscape highlights a limited number of genomic regions
that probably contain driver genes, including ZNF703, which we recently described as a
luminal B specific driver11, as well as somatic deletion events affecting key subunits of the
PP2A holoenzyme complex and MTAP, which have previously been under-explored in
breast cancer. The CNA-expression landscape also illuminates rare but potentially
significant events, including IGF1R, KRAS and EGFR amplifications and CDKN2B,
BRCA2, RB1, ATM, SMAD4, NCOR1 and UTX homozygous deletions. Although some of
these events have low overall frequencies (<1% patients) (Figs 2, Supplementary Fig. 15 and
Supplementary Tables 22–24), they may have implications for understanding therapeutic
responses to targeted agents, particularly those targeting tyrosine kinases or phosphatases.
Finally, because the integrative subgroups occur at different frequencies in the overall
population, focusing sequencing efforts on representative numbers from these groups will
help to establish a comprehensive breast cancer somatic landscape at sequence-level
resolution. For example, a significant number (~17%, n = 167 in the discovery cohort) of
breast cancers are devoid of somatic CNAs, and are ripe for mutational profiling. Our work
provides a definitive framework for understanding how gene copy number aberrations affect
gene expression in breast cancer and reveals novel subgroups that should be the target of
future investigation.
METHODS SUMMARY
All patient specimens were obtained with appropriate consent from the relevant institutional
review board. DNA and RNA were isolated from samples and hybridized to the Affymetrix
SNP 6.0 and Illumina HT-12 v3 platforms for genomic and transcriptional profiling,
respectively. A detailed description of the experimental assays and analytical methods used
to analyse these data are available in the Supplementary Information.
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Figure 1. Germline and somatic variants influence tumour expression architecture
a, Venn diagrams depict the relative contribution of SNPs, CNVs and CNAs to genome-
wide, cis and trans tumour expression variation for significant expression associations
(Šidák adjusted P-value ≤0.0001).
b, Histograms illustrate the proportion of variance explained by the most significantly
associated predictor for each predictor type, where several of the top associations are
indicated.
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Figure 2. Patterns of cis outlying expression refine putative breast cancer drivers
A genome-wide view of outlying expression coincident with extreme copy number events in
the CNA landscape highlights putative driver genes, as indicated by the arrows and
numbered regions. The frequency (absolute count) of cases exhibiting an outlying
expression profile at regions across the genome is shown, as is the distribution across
subgroups for several regions in the insets. High-level amplifications are indicated in red
and homozygous deletions in blue. Red asterisks above the bar plots indicate significantly
different observed distributions than expected based on the overall population frequency (χ2
test, P < 0.0001).
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Figure 3. Trans-acting aberration hotspots modulate concerted molecular pathways
a, Manhattan plot illustrating cis and trans expression-associated copy number aberrations
from the eQTL analysis (top panel). The matrix of significant predictor–expression
associations (adjusted P-value ≤0.0001) exhibits strong off-diagonal patterns (middle panel),
and the frequency of mRNAs associated with a particular copy number aberration further
illuminates these trans-acting aberration hotspots (bottom panel). The directionality of the
associations is indicated as follows: cis: positive, red; negative, pink; trans: positive, blue;
negative, green. b, Enrichment map of immune response modules in the trans-associated
TRA network, where letters in parentheses represent the source database as follows: b, NCI-
PID BioCarta; c, cancer cell map; k, KEGG; n, NCI-PID curated pathways; p, PANTHER; r,
Reactome.
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Figure 4. The integrative subgroups have distinct copy number profiles
Genome-wide frequencies (F, proportion of cases) of somatic CNAs (y-axis, upper plot) and
the subtype-specific association (−log10 P-value) of aberrations (y-axis, bottom plot) based
on a χ2 test of independence are shown for each of the 10 integrative clusters. Regions of
copy number gain are indicated in red and regions of loss in blue in the frequency plot
(upper plot). Subgroups were ordered by hierarchical clustering of their copy number
profiles in the discovery cohort (n = 997). For the validation cohort (n = 995), samples were
classified into each of the integrative clusters as described in the text. The number of cases
in each subgroup (n) is indicated as is the in-group proportion (IGP) and associated P-value,
as well as the distribution of PAM50 subtypes within each cluster.
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Figure 5. The integrative subgroups have distinct clinical outcomes
a, Kaplan–Meier plot of disease-specific survival (truncated at 15 years) for the integrative
subgroups in the discovery cohort. For each cluster, the number of samples at risk is
indicated as well as the total number of deaths (in parentheses). b, 95% confidence intervals
for the Cox proportional hazard ratios are illustrated for the discovery and validation cohort
for selected values of key covariates, where each subgroup was compared against IntClust 3.
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